HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kratom Group Contests FDA's Opioid Finding, Requests Joint Meeting With NIDA

This article was originally published in The Rose Sheet

Executive Summary

American Kratom Association accuses FDA of using “inaccurate, extrapolated and distorted” information on adverse events and deaths allegedly associated with the use of kratom to justify scheduling it as a controlled substance. After FDA Commissioner Gottlieb says the criticism is unfounded and kratom has no future as a dietary ingredient in the US, the group asks for joint meeting with NIDA to discuss "public health policy that allows for consumers to safely use natural kratom."

You may also be interested in...



Kratom Industry GMPs Target Swaying FDA By Exceeding Agency Standards

“We want to show that the kratom industry is maturing, that people want to do the right thing,” says AKA Chairman Dave Herman. The standards go “well beyond” FDA's minimum GMP requirements for dietary supplements, AKA says.

Clinical Trials For Supplement Claims Not An FTC Rule, But A Standard

FTC Bureau of Consumer Protection official Richard Cleland takes on the hot-button issue by explaining that a supplement health or structure/function claim doesn't need support from research with the size and scope of studies looking at the safety and efficacy of a drug ingredient proposed for a certain indication. Supplement ad claims, though, still need competent and reliable scientific evidence as support.

Kratom Group Sharpens Criticism Of 'Opioid' Finding In FDA's Report To DEA

American Kratom Association realizes FDA could have significant influence on DEA decision on whether to schedule kratom constituent ingredients as controlled substances. The association and experts on kratom say FDA's, which concluded that mitragynine and 7-hydroxymitragynine are opioids and use of kratom is dangerous, contains numerous inaccuracies and incorrect conclusions.

Related Content

Topics

UsernamePublicRestriction

Register

RS121784

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel